Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model at Digestive Disease Week 2024

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST – Abivax SA

GlobeNewswireMay 8 01:30

Abivax Annual Ordinary and Extraordinary General Meeting of May 30, 2024 - Availability of the Preparatory Documents

Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or

GlobeNewswireMay 7 15:00

Abivax Shares Are Trading Higher After Guggenheim and Piper Sandler Initiated Coverage on the Stock With Bullish Ratings.

Abivax Shares Are Trading Higher After Guggenheim and Piper Sandler Initiated Coverage on the Stock With Bullish Ratings.

BenzingaApr 29 06:38

Guggenheim Starts Abivax With Buy Rating, $50 Price Target

Guggenheim Starts Abivax With Buy Rating, $50 Price Target.

MT NewswiresApr 29 06:06

Abivax (ABVX.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $42.00.

Abivax (ABVX.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $42.00.

Zhitong FinanceApr 29 04:40

Piper Sandler Initiates Coverage On Abivax With Overweight Rating, Announces Price Target of $42

Piper Sandler analyst Christopher Raymond initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target of $42.

BenzingaApr 29 04:39